DDInter6 DDInter336
Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αvβ3) receptor found on platelets and vessel wall endothelial and smooth muscle cells.
Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is a nonsteroidal anti-inflammatory drug (NSAID) which is known for its decreased risk of causing gastrointestinal bleeding compared to other NSAIDS. It is used to manage symptoms of various types of arthritis pain and in familial adenomatous polyposis (FAP) to reduce precancerous polyps in the colon. It is marketed by Pfizer under the brand name Celebrex, and was initially granted FDA approval in 1998. Interestingly, selective COX-2 inhibitors (especially celecoxib), have been evaluated as potential cancer chemopreventive and therapeutic drugs in clinical trials for a variety of malignancies.
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) palliates {v} (Disease) systemic scleroderma
systemic scleroderma {u} (Disease) is palliated by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Epoprostenol
Epoprostenol {u} (Compound) causes {v} (Side Effect) Nausea
Nausea {u} (Side Effect) is caused by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Escitalopram
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tolmetin
Tolmetin {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Nonsteroidal Anti-inflammatory Compounds {u} (Pharmacologic Class) includes {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Icosapent
Icosapent {u} (Compound) downregulates {v} (Gene) RBM34
RBM34 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) PTGS2
PTGS2 {u} (Gene) is bound by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) downregulates {v} (Gene) RRS1
RRS1 {u} (Gene) is upregulated by {v} (Compound) Celecoxib
Abciximab {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Treprostinil
Treprostinil {u} (Compound) upregulates {v} (Gene) ZMIZ1
ZMIZ1 {u} (Gene) is downregulated by {v} (Compound) Celecoxib
Abciximab {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Clopidogrel {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Celecoxib
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) palliates systemic scleroderma (Disease) and systemic scleroderma (Disease) is palliated by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram (Compound) upregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) and Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class) includes Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Icosapent and Icosapent (Compound) downregulates RBM34 (Gene) and RBM34 (Gene) is downregulated by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates PTGS2 (Gene) and PTGS2 (Gene) is bound by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) downregulates RRS1 (Gene) and RRS1 (Gene) is upregulated by Celecoxib (Compound)
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) upregulates ZMIZ1 (Gene) and ZMIZ1 (Gene) is downregulated by Celecoxib (Compound)
Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Celecoxib (Compound)